Clinical Trials Logo

Filter by:
NCT ID: NCT01387594 Completed - Ulcerative Colitis Clinical Trials

Evaluate PF-00547659 On Cerebrospinal Fluid Lymphocytes In Volunteers With Crohn's Disease Or Ulcerative Colitis Who Failed Or Did Not Tolerate Anti-TNFs

TOSCA
Start date: May 3, 2012
Phase: Phase 1
Study type: Interventional

Study is designed to show a lack of effect on white blood cells circulating in the spinal fluid.

NCT ID: NCT01387269 Completed - Clinical trials for Non-Small Cell Lung Cancer

Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1)

Start date: July 2011
Phase: Phase 3
Study type: Interventional

The administration of Anamorelin in patients with Stage III-IV non-small cell lung cancer-cachexia (NSCLC-C) is expected to increase appetite, lean body mass, weight gain, and muscle strength.

NCT ID: NCT01386580 Completed - Breast Cancer Clinical Trials

An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.

Start date: July 2011
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the safety, tolerability, and pharmacokinetics (PK) of 2B3-101 both as single agent and in combination with trastuzumab. Furthermore, the study will explore the preliminary antitumor activity of 2B3-101 as single agent in patients with with solid tumors and brain metastases or recurrent malignant glioma as well as in patients with various forms of breast cancer with and in combination with trastuzumab in HER2+ breast cancer patients with brain metastases.

NCT ID: NCT01386528 Completed - Clinical trials for Congenital Bleeding Disorder

Efficacy and Safety of NNC-0156-0000-0009 During Surgical Procedures in Subjects With Haemophilia B

paradigm™ 3
Start date: June 7, 2012
Phase: Phase 3
Study type: Interventional

This trial is conducted in Africa, Asia, Europe and the United States of America (USA). The aim of the trial is to evaluate the safety and efficacy of NNC-0156-0000-0009 (nonacog beta pegol) during surgical procedures in patients with haemophilia B.

NCT ID: NCT01385696 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease (COPD)

Study Evaluating Preference, Satisfaction and Ease of Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD) Diagnosed Patients

Start date: June 2011
Phase: Phase 3
Study type: Interventional

Preference study: Genuair vs HandiHaler inhalers in COPD patients.

NCT ID: NCT01384968 Completed - Clinical trials for Acute Nitrate Ingestion on Athletic Performance

Acute Nitrate Supplementation in Cyclists

Start date: July 2011
Phase: N/A
Study type: Interventional

Six days of dietary nitrate (NO3-) supplementation in the form of beetroot juice (~0.5 L•d-1; 5.1-11.2 mmol NO3- •d-1) has been purported to reduce pulmonary oxygen uptake (VO2) during submaximal exercise and increase tolerance to high-intensity workloads. These results suggest that dietary nitrate supplementation has the potential to act as an ergogenic aid. Recently, we assessed submaximal oxygen uptake and 10 km time trial performance after 6 d of dietary nitrate supplementation in trained cyclists. We demonstrated an improvement in time trial performance compared to the nitrate-depleted placebo. However, the minimal dosage and duration of nitrate supplementation that is needed to elicit these performance effects remain largely unknown. Therefore, the purpose of the study is to assess performance capacity following an acute dose of nitrate supplementation consumed 3 h prior to the onset of exercise in trained cyclists. We will test the hypothesis that a single dose (140 mL; ~8 mmol NO3-) of dietary nitrate supplementation in the form of beetroot juice, ingested 3 h prior to exercise will improve time trial performance in trained cyclists compared to a nitrate-depleted placebo.

NCT ID: NCT01383863 Completed - Clinical trials for Advanced Prostate Cancer

A Long-term Observational Study Cohort in Patients With Advanced Prostate Cancer

TRIPTOCARE LT
Start date: October 2011
Phase:
Study type: Observational

The purpose of the protocol is to assess the rate of castration resistance, disease progression and overall survival over a 3-year period post-androgen deprivation therapy (ADT) induction in a study cohort of patients with advanced disease.

NCT ID: NCT01383733 Completed - Neoplasms Clinical Trials

A Study of RO5458640 in Patients With Advanced Solid Tumors

Start date: July 2011
Phase: Phase 1
Study type: Interventional

This multicenter, open-label, multiple ascending dose study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RO5458640 in patients with advanced solid tumors. Cohorts of patients will receive ascending doses of RO5458640 intravenously, either weekly or every 2 weeks or every 3 weeks, until disease progression or unacceptable toxicity occurs.

NCT ID: NCT01383421 Completed - Clinical trials for Rheumatoid Arthritis

Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

PASSION
Start date: September 2011
Phase: N/A
Study type: Observational

Post-marketing observational study to determine the effectiveness and patient satisfaction with adalimumab treatment in patients with Rheumatoid Arthritis in relation to utilization of a Patient Support Program (PSP).

NCT ID: NCT01381874 Completed - Postmenopausal Clinical Trials

A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy

Start date: August 24, 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the safety and efficacy of oral abiraterone acetate plus oral prednisone and oral abiraterone acetate plus oral prednisone plus oral exemestane, each compared with oral exemestane alone, in postmenopausal women with estrogen receptor-positive (ER+) metastatic (spreading) breast cancer that has relapsed after treatment with letrozole or anastrozole.